Regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by bone resorptive factors in osteoblastic cells
- 1 November 2000
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 185 (2) , 207-214
- https://doi.org/10.1002/1097-4652(200011)185:2<207::aid-jcp5>3.0.co;2-j
Abstract
In addition to their stimulating function on osteoclastic bone resorption, bone resorptive factors may regulate proteinases and related factors in osteoblastic cells to degrade bone matrix proteins. This study investigated the regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by bone resorptive factors in the cultures of mouse osteoblastic MC3T3‐E1 cells, mouse primary osteoblastic (POB) cells, and neonatal mouse calvariae. Expression of either MMP‐2, ‐3, ‐9, ‐11, ‐13, and ‐14 or TIMP‐1, ‐2, and ‐3 was detected in MC3T3‐E1 cells and POB cells. When the bone resorptive factors parathyroid hormone, 1,25‐dihydroxyvitamin D3, prostaglandin E2, interleukin‐1β (IL‐1β), and tumor necrosis factor‐α (TNF‐α) were added to the cell cultures, MMP‐13 mRNA levels were found predominantly to increase by all resorptive factors in the three cultures. mRNA levels of either MMP‐3 and ‐9 or TIMP‐1 and ‐3 were found to increase mainly by the cytokines IL‐1β and TNF‐α. BB94, a nonselective MMP inhibitor, neutralized the 45Ca release stimulated by these resorptive factors to an extent similar to that of calcitonin, strongly suggesting that bone resorptive factors function at least partly through MMP formation. We propose that MMP‐13 mRNA expression in osteoblastic cells may play an important role in stimulating matrix degradation by both systemic and local resorptive factors, whereas either MMP‐3 and ‐9 or TIMP‐1 and ‐3 might modulate matrix degradation by local cytokines only. J. Cell. Physiol. 185:207–214, 2000.Keywords
This publication has 26 references indexed in Scilit:
- Trendsin Molecular Medicine: Matrix metalloproteinases and their inhibitors in tumour growth and invasionAnnals of Medicine, 1999
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Membrane‐Type‐2 Matrix Metalloproteinase Can Initiate the Processing of Progelatinase A and is Regulated by the Tissue Inhibitors of MetalloproteinasesEuropean Journal of Biochemistry, 1997
- Molecular Cloning and Characterization of Human Tissue Inhibitor of Metalloproteinase 4Journal of Biological Chemistry, 1996
- Cellular Mechanisms for Human Procollagenase-3 (MMP-13) ActivationJournal of Biological Chemistry, 1996
- Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor‐1 in primary cultures of rat calvarial osteoblastsJournal of Cellular Physiology, 1995
- The synthesis of collagenase, gelatinase-A (72 kDa) and -B (95 kDa), and TIMP-1 and -2 by human osteoblasts from normal and arthritic boneBone, 1995
- Osteoclast molecular phenotyping by random cDNA sequencingBone, 1995
- High expression of 92-kD type IV collagenase (gelatinase B) in the osteoclast lineage during mouse developmentThe Journal of cell biology, 1994
- Bone-resorbing agents promote and interferon-γ inhibits bone cell collagenase productionJournal of Bone and Mineral Research, 1988